This a phase II/III randomized, double-blind, placebo-controlled, parallel group, adaptive design, multi-center study to evaluate the efficacy and safety of ICP-332 in subjects with non-segmental vitiligo。The study consisted an phase 2 part and an phase 3 part.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
603
ICP-332 will be administered as tablet
ICP-332 Placebo will be administered as tablet
Phase2: Percent change from baseline in facial vitiligo area scoring index (F-VASI) at week 24.
Time frame: 24 weeks
Phase3: Proportion of subjects achieving F-VASI 75 at Week 52.
Time frame: 52 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
The First Affiliated Hospital of Wannan Medical College
Wuhu, Anhui, China
NOT_YET_RECRUITINGThe Second Affiliated Hospital of Wannan Medical College
Wuhu, Anhui, China
NOT_YET_RECRUITINGPeking University Third Hospital
Beijing, Beijing Municipality, China
NOT_YET_RECRUITINGBeijing Chao-yang Hospital,Capital Medical University
Beijing, Beijing Municipality, China
NOT_YET_RECRUITINGBeijing Tongren Hospital
Beijing, Beijing Municipality, China
NOT_YET_RECRUITINGThe First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
NOT_YET_RECRUITINGChongqing Traditional Chinese Medicine Hospital
Chongqing, Chongqing Municipality, China
RECRUITINGUnion Hospital affiliated to Fujian Medical
Fuzhou, Fujian, China
NOT_YET_RECRUITINGThe First Affiliated Hospital of Fujian Medical
Fuzhou, Fujian, China
NOT_YET_RECRUITINGSun Yat-sen Memorial Hospital,Sun Yat-sen University
Guangzhou, Guangdong, China
NOT_YET_RECRUITING...and 35 more locations